

RESEARCH ARTICLE

Open Access



# Bactericidal activities and biochemical features of 16 antimicrobial peptides against bovine-mastitis causative pathogens

Hye-sun Cho<sup>1</sup>, Dohun Kim<sup>1</sup>, Hyoim Jeon<sup>1</sup>, Prathap Somasundaram<sup>1</sup>, Nagasundarapandian Soundrarajan<sup>1</sup> and Chankyu Park<sup>1\*</sup>

## Abstract

Mastitis, often caused by bacterial infection, is an inflammatory condition affecting the mammary glands. The condition is particularly prevalent in dairy cattle. Current treatment of bovine mastitis heavily relies on the use of antibiotics. To identify alternative solutions to antibiotic use, we evaluated the antimicrobial activity of 14 cathelicidins reported from 10 animal species. In conjunction, we assessed two bacteriocins against the bovine-mastitis causative bacterial panel, consisting of *Escherichia coli*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Bacillus cereus*, *Enterococcus faecalis*, *Streptococcus agalactiae*, *Streptococcus dysgalactiae*, and *Streptococcus equi*. Among the antimicrobial peptides (AMPs), cc-CATH3, ML-CATH, and PD-CATH proved to be highly active (minimum inhibitory concentration of 2–41 µg/mL, 0.2–10.3 µM) against all bacterial strains in the panel and field isolates from milk, with elevated somatic cell counts ( $\geq 500,000$  cells/mL). Of the AMPs tested in this study, ML-CATH presented the highest level of effectiveness in controlling mastitis-associated bacterial strains while also possessing minimal cytotoxicity and functional stability against pH change and a high salt condition. The results of in silico analyses on the biochemical features of 12 helical cathelicidins revealed that the charge of AMPs appears to be a major determinant in killing Gram-negative bacteria. Furthermore, we observed a unique motif, " $N_{(n\geq 3)}-P_{(n\geq 1)}-N_{(n\geq 3)}$ ", from the sequences of PMAP-36, cc-CATH3, ML-CATH, and PD-CATH that exhibits potent antimicrobial activity against a broad spectrum of bacteria compared to others. Our findings support the proposition that AMPs could serve as effective antimicrobial alternatives to conventional antibiotics in treating complex animal diseases caused by microbial infection, such as bovine mastitis.

**Keywords** Bovine mastitis, antimicrobial peptides, Cathelicidins, bacteriocins, biochemical properties

## Introduction

Mastitis, a highly prevalent and costly disease for the dairy industry, is an inflammatory process of the mammary gland primarily caused by microbial infection [1]. Mastitis-causing bacteria are classified as either contagious or environmental microorganisms, depending on

their distribution and interaction with the teat and teat duct [2]. Contagious mastitis can be transferred from cow to cow and is caused by bacterial species such as *S. aureus*, *S. agalactiae*, *S. dysgalactiae*, and *Corynebacterium* spp. In contrast, environmental pathogens such as coliform bacteria, other streptococci, *Enterococcus* spp. and *Pseudomonas* spp., which are considered opportunistic pathogens responsible for subclinical mastitis, can be spread to other cows through a contaminated barn environment and the milking process [3–5]. Consequently, contagious mastitis is typically controlled in dairy herds by post-milking teat dipping, total dry cow therapy,

Handling editor: Marcelo Gottschalk.

\*Correspondence:

Chankyu Park

chankyu@konkuk.ac.kr

<sup>1</sup> Department of Stem Cell and Regenerative Biotechnology, Konkuk University, Hwayang-Dong, Kwangjin-Gu, Seoul, Republic of Korea



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

culling, therapeutic treatment, and proper maintenance of the milking equipment [6]. Clinical mastitis caused by environmental pathogens is the leading issue for well-managed low-somatic cell count (SCC) herds. In addition, environmental mastitis affects all dairy herds, and its relative importance increases even when contagious mastitis is under control [7].

Several strategies have been proposed to manage mastitis in herds, such as diagnosing the condition, separating affected animals, and improving hygiene and treatment protocols. Some of these practices have been implemented to improve dairy cattle health, milk quality, food safety, well-being, and farm productivity. However, the treatment for bovine mastitis relies heavily on the use of antibiotics [3, 8]. While dry cow antibiotic therapy has helped reduce the incidence of mastitis, the emergence of antibiotic-resistant pathogens has raised serious concerns [3]. Considering the complexity of the disease, reflected by the numerous causative pathogens, the variety and magnitude of the physiological responses, and the variation in the efficacy of control measures, alternative approaches are much needed [3]. Up to 200 different microbes have been isolated from mastitis cases, including primarily bacteria, fungi, and even monocellular algae. Nonetheless, staphylococci, streptococci, and coliforms appear to be most commonly associated with intramammary infections [4, 9, 10].

In this study, we propose that endogenous antimicrobial peptides (AMPs) can provide an alternative approach to combat the threat from infectious diseases caused by bacterial pathogens, including multidrug-resistant (MDR) bacteria. AMPs are evolutionarily ancient and pervasive components of the innate immune system in multicellular organisms such as animals, plants, and insects [11]. To date, several AMP families have been identified, either derived from a common ancestor (belonging to a genetic family) or having independently evolved from similar properties in primary or secondary structures [12, 13]. These peptides exhibit direct antibacterial effects against various microbes due to the cationic and amphipathic structures capable of disrupting the microbial membrane [14].

AMPs can be divided into many subtypes according to different criteria, such as their origin, size, structure, amino acid sequence, biological action, acting mechanism, and conserved motif [15, 16]. Despite this division, most AMPs possess positively charged residues, with a minor subgroup containing anionic amino acids [17]. Their secondary structure further categorises them into four classes: alpha-helical, beta-sheet, extended, and looped peptides [18]. Several AMPs of interest have been engineered to enhance antimicrobial activity and reduce their cytotoxic effects based on their structural and

biochemical properties [19–21]. However, our understanding of these molecules' biological functions and mechanisms is still limited.

For this study, based on available information from previous research, we selected two bacteriocins and 16 AMPs comprising 14 cationic cathelicidins from 10 animal species. We evaluated their antimicrobial activities against the bacterial panel associated with bovine mastitis, including field isolates. We also tested these molecules' cytotoxicity and functional stability in different physiological conditions. As a result, we presented a suitable AMP candidate for controlling a broad spectrum of mastitis-causing bacterial species in cattle. The information accumulated on the functional characteristics of the AMPs compared to the structural and biochemical characteristics and peptide sequences of the individual AMPs in this study contributes to developing a new class of therapeutic agents capable of controlling diverse bacterial diseases in animals.

## Materials and methods

### Preparation of antimicrobial peptides

Using a commercial service (GenScript, Piscataway Township, NJ, United States), AMPs, including  $\Delta$ ModoCath1,  $\Delta$ ModoCath5,  $\Delta$ ModoCath6, PMAP-36, PR-35,  $\Delta$ Pb-CATH4,  $\Delta$ Hg-CATH, BMAP-28, EA-CATH1, cc-CATH3, HA-CATH, ML-CATH, and PD-CATH were synthesised by solid-phase peptide synthesis and purified by high-performance liquid chromatography (HPLC). Bacteriocins, nisin, and lysostaphin were purchased commercially (Sigma Aldrich, St. Louis, MO, USA; chemicals without source information in this study were purchased from Sigma Aldrich).

Recombinant PG1 was produced by employing previously reported methods of green fluorescent protein (GFP)-scaffold system [22, 23]. In brief, the DL4GFP-PG1 construct-transformed BL21 (DE3) cells were grown in 1 L of Luria–Bertani (LB) medium (BD Bioscience, Franklin Lakes, NJ, USA) at 37 °C and 220 rpm. To induce the expression of GFP-PG1 fusion protein, 0.1 mM isopropyl  $\beta$ -D-1-thiogalactopyranoside at 0.8–1.0 OD<sub>600</sub> was used. After 5 h of induction, cells were harvested by centrifugation at 9900  $\times$ g for 10 min at 4 °C and then disrupted by sonication (Sonopuls HD 2070; Bandelin, Berlin, Germany) in the lysis buffer (20 mM sodium phosphate buffer at pH 7.4 containing 150 mM sodium chloride, 0.1 mM phenylmethylsulfonyl fluoride, and 1 mM dithiothreitol).

The insoluble fraction was separated by centrifugation at 20 000  $\times$ g for 20 min at 4 °C. To remove cellular debris, nucleic acids, and cytosolic proteins, DNase (0.01 mg/mL), lysozyme (0.1 mg/mL), and 0.5% Triton-X 100 were added to the insoluble fractions and incubated at room

temperature (24 °C) for 20 min. The pellets were washed thrice in the lysis buffer without adding DNase and lysozyme. The insoluble fraction was dissolved in urea buffer (20 mM sodium phosphate buffer at pH 7.4 containing 8 M urea, 500 mM sodium chloride, and 30 mM imidazole). The target proteins were purified using affinity chromatography with the HisTrap HP column (GE Healthcare, Chicago, IL, USA). After undergoing dialysis and lyophilisation, the insoluble precipitates were dissolved in 70% formic acid and subjected to the addition of cyanogen bromide (CNBr). The mixture was then incubated for 24 h to cleave the N- and C-terminal GFPs flanking PG1.

After removing CNBr by lyophilisation, the target peptides were purified using a preparative reverse-phase HPLC (RP-HPLC) column (DeltaPak C18 Prep column 19, 300 mm; Waters, Tokyo, Japan) in a linear gradient of acetonitrile (5–90%)/0.1% trifluoroacetic acid for 60 min at a flow rate of 12 mL/min. The target peptides were collected at optical densities of 214 nm and 280 nm. The target proteins collected before CNBr cleavage and after RP-HPLC were visualised on both 12% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and 16% Tris-Tricine PAGE, respectively. The collected RP-HPLC fractions were lyophilised and suspended in 20 mM sodium phosphate buffer at pH 7.4 containing 8 M urea, 5 mM reduced glutathione, and 0.5 mM oxidised glutathione to install disulfide bonds in PG1 peptides. After dialysis against deionised water, the mixture was lyophilised and quantified using the Bradford assay (Bio-Rad, Hercules, California, USA). The produced peptide was aliquoted and stored at -20 °C until use.

#### Standard bacterial strains and culture

The standard bacterial strains used for antimicrobial activity assays include *Staphylococcus aureus* ATCC (American Type Culture Collection, Manassas, VA, USA) 6538, *Bacillus cereus* ATCC 10876, *Enterococcus faecalis* ATCC 29212, *Streptococcus agalactiae* ATCC 27956, *Streptococcus dysgalactiae* ATCC 27957, *Streptococcus equi* subsp. *zooepidemicus* ATCC 43079, *Escherichia coli* ATCC 25922, and *Pseudomonas aeruginosa* ATCC 27853. Most bacterial strains were cultured in LB medium except for *E. faecalis* and streptococci, which were cultivated in brain heart infusion (BHI) broth (BD Bioscience).

#### Isolation of bacteria from milk

From a commercial dairy herd in Ansong, South Korea, and in line with the Korean Ministry of Food and Drug Safety (MFDS; 2018) protocol, a total of 56 milk samples with elevated SCC ( $\geq 500,000$ ) were collected from 14 cows experiencing subclinical mastitis. The first streams

of milk were discarded, and the subsequent samples were stored below 4 °C. A 1 mL aliquot of the samples was subject to cultivation within 24 h after collection. The remaining aliquots were immediately frozen at -20 °C for future experiments. The tenfold serial dilutions in 0.9% saline (Sigma-Aldrich) were conducted in triplicate, and bacteria were isolated and enumerated using the spread plate method. The serial dilutions were plated onto (i) Mueller–Hinton (MH) agar at 37 °C for 24 h; (ii) MacConkey agar (MCA) at 37 °C for 24 h, which selects for enterobacteria; and (iii) Tryptic soy agar (TSA) supplemented with 5% (v/v) defibrinated horse blood (MBCell, Kisanbio, Seoul, Korea) at 37 °C for 48 h. All plates were cultivated aerobically. Visual culture characteristics of bacterial colonies on agar plates, including haemolytic characteristics, were assessed.

#### Bacterial classification using 16S ribosomal RNA sequencing

As outlined in a previous study [24], sequence analysis of the 16S small subunit ribosomal RNA gene was conducted for the taxonomic classification of field isolates. A single bacterial colony was transferred into 20  $\mu$ L of sterile water in a polymerase chain reaction (PCR) tube (0.2 mL) and incubated at 100 °C for 15 min. Subsequently, 20  $\mu$ L of PCR reactions comprising 2  $\mu$ L of bacterial lysates, 2.0  $\mu$ L of 10 $\times$ buffer (10 mM Tris–HCl, 50 mM KCl), 1.2  $\mu$ L of 25 mM MgCl<sub>2</sub>, 2  $\mu$ L of 10 mM dNTP, 0.7  $\mu$ L of each primer (10 pmol/ $\mu$ L), and 0.2  $\mu$ L of Taq DNA polymerase (1 U, SolGent, Daejeon, Korea) were conducted using a cycling profile. The profile consisted of 95 °C for 5 min, 30 cycles of 95 °C for 1 min, 50 °C for 30 s, and 72 °C for 1.5 min. The final extension was at 72 °C for 10 min.

The primer sequences for amplifying 16S rRNA were 5'-AGAGTTTTCATCCTGGCTCAG-3' and 5'-GGT TACCTTGTTACGACTT-3' for forward and reverse, respectively [25]. The PCR products were purified using a MinElute Kit (Qiagen, Crawley, West Sussex, UK) and sequenced using AmpliTaq polymerase and BigDye Terminator (Applied Biosystems, Foster City, CA, USA) using the same primers in both directions while following the manufacturers' instructions. The reactions were run on an ABI PRISM 3730 DNA Analyzer (Applied Biosystems). The species identity of each colony was determined using blast analysis against the National Center for Biotechnology Information (NCBI) rRNA/ITS databases [26].

#### Antibacterial activity assay for antimicrobial peptides and bacteriocins

The minimum inhibitory concentration (MIC) was determined by following the manufacturer's protocol

and Clinical and Laboratory Standards Institute (CLSI) guidelines (2018) using a colourimetric method specified by the Microbial Viability Assay Kit-WST (Dojindo, Kumamoto, Japan). Four colonies of each bacterium were inoculated into 5 mL of LB medium and incubated at 37 °C for 4–6 h. The cells were then washed twice with sterile saline (0.9% NaCl) and seeded into a single well of a 96-well plate at a density of  $1.5 \times 10^5$  cells/well, adjusting by McFarland standard 0.5. Subsequently, 180  $\mu$ L/well of fresh MH broth (BD Bioscience) was added to the plate. Ampicillin, chloramphenicol, and gentamicin sulfate were used as controls for antimicrobial activity.

Different concentrations of each peptide and reference antibiotics (up to 40  $\mu$ g/mL) were serially diluted in 10  $\mu$ L of MH broth and added to each well. The plate was incubated at 37 °C for 6 h, using BHI broth to culture slow-growing fastidious strains, including *E. faecalis*, *A. hydrophila*, *C. simulans*, *G. halophytocola*, and streptococci. Cation-adjusted Mueller Hinton II broth (CAMHB) was employed to cultivate *P. aeruginosa*. Afterwards, 10  $\mu$ L of the colouring reagent was added, and cells were incubated at 37 °C for 2 h. UV absorbance was measured for each well at 450 nm using a microplate spectrophotometer (xMark spectrophotometer; Bio-Rad, Hercules, CA, USA). The MIC values were determined when the absorbance difference between treatments and blanks (media and colouring reagent only) decreased to <0.05. Experiments were conducted in triplicate.

#### Estimation of haemolytic and cytotoxic activity

Human keratinocytes (HaCaT) and pig kidney fibroblast cells (PK15, ATCC CCL-33) were cultured in Dulbecco's modified Eagle's medium (DMEM; Hyclone™, Logan, UT, USA) and supplemented with 10% foetal bovine serum (FBS; Hyclone™, Logan, UT, USA), 1% penicillin–streptomycin (Hyclone™) at 37 °C, and 5% CO<sub>2</sub> up to 80% confluence. Cell substratum adhesion was disrupted using Accutase (Innovative Cell Technologies, San Diego, CA, USA). A total of  $4 \times 10^4$  cells were incubated for 24 h at 37 °C and 5% CO<sub>2</sub> in each well of a 96-well plate containing 64 and 160  $\mu$ g/mL of each peptide.

A positive control for complete cell lysis was established using Triton-X100 (1%), and untreated cells were used as the negative control. After incubation, the medium was removed from the wells and replaced with 10  $\mu$ L of colouring solution (Cell Proliferation Reagent WST-1™) and 100  $\mu$ L of DMEM (Hyclone™), per the manufacturer's protocol. Each well absorbance was measured at 440 nm (peptide-treated and control) and 650 nm (background). These measurements were recorded as the optical density (OD) using a microplate reader (xMark™ spectrophotometer; Bio-Rad, CA, USA). Cell viability was calculated using the following equation:

#### Cell Viability (%)

$$= 100 \times \frac{(OD_{peptide} - OD_{background})}{(OD_{negative} - OD_{background})}$$

All experiments were performed in triplicate.

The experimental procedures were conducted in accordance with the guidelines approved by the Institutional Animal Care and Use Committee (IACUC) of Konkuk University, Seoul, Korea, and bovine blood was collected from a cow at a local farm using a BD Vacutainer® Sodium Heparin (BD Bioscience) to analyse haemolytic activity. Plasma was removed from the whole blood by centrifugation. Erythrocytes were washed thrice with phosphate-buffered saline (PBS, pH 7.4) and resuspended in PBS at a concentration of 2% (v/v). Subsequently, 100  $\mu$ L of the erythrocyte suspension was added to each well of a 96-well microtiter plate. The plate contained an equal volume of the peptides in PBS with different concentrations of 10, 20, 40, 80, and 160  $\mu$ g/mL. Triton-X 100 (1%) and PBS were used as positive and negative controls, respectively. Plates were incubated at 37 °C for 1 h. The release of haemoglobin into the supernatant was monitored by measuring the change in OD at 410 nm using a microplate reader (xMark™ spectrophotometer; Bio-Rad). Results from three independent experiments were pooled. Hemolysis was calculated using the formula:

#### Hemolytic Percentage (%)

$$= 100 \times \frac{(OD_{peptide} - OD_{negative})}{(OD_{positive} - OD_{negative})}$$

All experiments were carried out in triplicate.

#### Analysis of the functional stability of AMPs under different physiological conditions

The MICs against *E. coli* (ATCC 25922) for cc-CATH3, ML-CATH, and PD-CATH in 150 mM NaCl and different pH (pH 5, 6, and 7) that were adjusted using acetic acid (Sigma Aldrich) were determined as described above. For serum stability assay, each AMP at four different concentrations was dissolved in 50% (v/v) FBS (Hyclone™) and incubated at 37 °C for 0, 60, and 120 min, respectively. As described in a previous study [27],  $\Delta$ Hg-CATH was used as a control for serum sensitivity. The antimicrobial activity of cc-CATH3, ML-CATH, and PD-CATH against *E. coli* was assessed for each condition as above. All experiments were conducted in triplicate.

#### In silico analysis of biochemical features

Amino acid sequences, antimicrobial activities, and structure information of publicly available cathelicidins were obtained from DBAASP (Database of Antimicrobial

Activity and Structure of Peptides) [28]. The molecular weight and grand average of hydropathicity (GRAVY) scores for the primary peptide sequences of 16 selected AMPs were calculated using ProtParam [29]. The net charge value of each peptide at pH 7 was calculated using Protein Calculator v3.4 [30], assuming the pKa value of all residues was equal to that of the individual amino acid. Peptide 2.0 [31] was used to calculate the hydrophobic and cationic percentages. Helical wheel projections and the prediction of secondary structures and solvent accessibility (SA) for alpha-helical cathelicidins were conducted using HeliQuest [32] and I-TASSER [33], respectively. The analysis of amino acid properties constituting AMPs and visualisation of tertiary structures was performed using PyMOL [34].

### Statistical analysis

The correlation coefficient ( $r$ ) between MIC and biochemical properties was calculated using the following equation [35]:

$$r(x, y) = \frac{\sum (x - \bar{x})(y - \bar{y})}{\sqrt{\sum (x - \bar{x})^2 \sum (y - \bar{y})^2}}$$

Welch's  $t$  test was used to test the difference in population means of MIC and biochemical properties [36].

## Results

### Identification of 13 bacterial strains from mastitis-affected milk

A total of 17 bacterial strains were isolated from culturing 56 milk samples of dairy cows with high SCC ( $\geq 500,000$  cells/mL). Isolation involved microbiological analyses assessing growth, colony morphologies, and haemolytic characteristics on the blood agar plate (Additional file 1). Using isolated bacterial colonies, PCR generated amplicons of approximately 1500 bp in size, thus corresponding to 16S rRNA. NCBI blast analysis was conducted against rRNA/ITS databases using the sequencing results of amplicons that matched 16S rRNA sequences of known bacterial species with coverage of  $>96\%$  and identity of  $>97\%$  (Additional file 1). Multiple colonies were isolated for *Staphylococcus chromogenes* ( $n=3$ ), *Corynebacterium amycolatum* ( $n=2$ ), and *Aerococcus viridans* ( $n=2$ ), with 13 different bacterial strains from mastitis-affected milk identified in this study.

### Diverse physicochemical properties of 14 cathelicidins and two bacteriocins

We selected 16 AMPs comprising 12 cathelicidins from eight mammalian species, including opossums ( $\Delta$ ModoCath1,  $\Delta$ ModoCath5, and  $\Delta$ ModoCath6), pigs (PMAP-36, PG1, and PR-35), mole rats ( $\Delta$ Hg-CATH),

horses (EA-CATH1), and bats (HA-CATH, ML-CATH, and PD-CATH). Additionally, we included a cathelicidin for each of the pythons ( $\Delta$ Pb-CATH4), quails (cc-CATH3), and two bacteriocins (nisin and lysostaphin) to identify AMPs with high therapeutic potential to bovine mastitis [27, 37–46]. The selected cathelicidins were previously reported to be highly potent against the tested bacterial strains, including *S. aureus*, *E. faecalis*, and *P. aeruginosa* at MICs  $< 10 \mu\text{M}$  despite the limits in available information on the activity spectrum and potency against reported bovine-mastitis causative pathogens [37, 39, 43, 44].

An in silico biochemical feature analysis of these selected 16 AMPs was conducted. For the in silico analysis of nisin, the primary sequence before post-translation modification was used as a query. Table 1 shows the amino acid sequences of each AMP and the results of the in silico biochemical feature analysis. The length and molecular weight distributions of these AMPs were 19–40 amino acids and 2.29–4.64 kDa, respectively.

The hydrophobic and cationic residues ratios were 22.22–68.57% and 22.50–44.00%, respectively. The charges at pH 7 ranged from +3.9 to +12.9. The peptide with the highest charge at pH 7 was PMAP-36 (+12.9), while  $\Delta$ Hg-CATH possessed the highest cationic residue rate (44.0%). The grand average of hydropathy (GRAVY) index score was negative ( $-1.32$  to  $-0.04$ ) for most cathelicidins except BMAP-28 (0.23) and cc-CATH3 (0.14) (Table 1). The hydrophobic moment values indicating helix properties of alpha-helical cathelicidins were 0.158–0.634. However, the hydrophobic face was not predicted in  $\Delta$ ModoCath1 and PD-CATH, showing a small hydrophobic moment (Figure 1).

### Bactericidal activities of cc-CATH3, PD-CATH and ML-CATH against all tested bacterial species

We evaluated the antimicrobial activity of the peptides in our AMP panel against eight standard bacterial strains. The evaluation consisted of two Gram-negative strains, *E. coli* and *P. aeruginosa*, and six Gram-positive strains, *S. aureus*, *B. cereus*, *E. faecalis*, *S. agalactiae*, *S. dysgalactiae*, and *S. equi* subsp. *zooepidemicus*. In antimicrobial activity analysis against the standard bacterial strains, PR-35 and  $\Delta$ ModoCath6 showed activity only against *E. coli* (ATCC 25922, Table 2).

Additionally,  $\Delta$ ModoCath5, HA-CATH, PG1,  $\Delta$ Pb-CATH4, EA-CATH1,  $\Delta$ ModoCath1, PMAP-36, BMAP-28, and  $\Delta$ Hg-CATH exhibited bactericidal activities against only some Gram-negative and Gram-positive strains with MICs that ranged between 3 and 43  $\mu\text{g}/\text{mL}$  (0.7–18.8  $\mu\text{M}$ ), while lacking activity against the rest of the strains (Table 2). Out of the bacteriocins tested, lysostaphin showed specific activity against *S. aureus* with

**Table 1** The physicochemical characteristics of analysed cathelicidins in this study

Names	Origin	Sequences	Length	Molecular weight (Da)	Net charge at pH 7	Hydrophobic residue (%)	Cationic residue (%)	GRAVY score
ΔModoCath1	<i>Monodelphis domestica</i>	VKRTKRGARRGLTKVLKKIFG-SIVKKAVSKGV	32	3510.37	11.9	37.50	37.50	-0.31
ΔModoCath5		WYQLIRTFGNLIHQYRKL-LEAYRKL RD	28	3623.27	5.1	35.71	28.57	-0.85
ΔModoCath6		VRRSRKGIKVPSPFVKVLKDV-VSESI S	27	3042.66	5.9	40.74	29.63	-0.19
PMAP-36	<i>Sus scrofa</i>	GRFRRLRKKTRKRLKKIGKVLK-WIPPIVGS IPLGCG	36	4157.22	12.9	41.67	36.11	-0.46
PG-1 <sup>a</sup>		MRRGRLCYCRRRFVCVGR	19	2291.82	5.8	22.22	33.33	-0.25
PR-35		RRRPRPPYLPRRPPPPFPRLP-PRIPPGFPPRFP	35	4223.1	8.9	68.57	25.71	-1.32
ΔPb-CATH4	<i>Python bivittatus</i>	TRSRWRRFIRGAGRFARRYGWR-IA	24	3052.55	8.9	37.50	37.50	-1.10
ΔHg-CATH	<i>Heterocephalus glaber</i>	SKFFRKARKKLGKGLQKIKN-VLRKY	25	3035.77	10.9	32.00	44.00	-1.08
BMAP-28	<i>Bos taurus</i>	GGLRSLGRKILRAWKKYGP I-IVPIIRIG	28	3131.89	6.9	50.00	25.00	0.23
EA-CATH1	<i>Equus asinus</i>	KRRGVS TTRYQFLMIHLLRPK-KLFA	25	3060.75	7.1	44.00	32.00	-0.35
cc-CATH3	<i>Coturnix coturnix</i>	RVRRFWPLVPVAINTVAAGIN-LYKAI RRK	29	3379.11	6.9	58.62	24.14	0.14
HA-CATH	<i>Hipposideros armiger</i>	ILGRLRDLLRRGGRKIGQGLER-IGRIQGF FSNREPMEES	40	4640.37	3.9	32.50	22.50	-0.82
ML-CATH	<i>Myotis lucifugus</i>	LNPLIKAGIFILKHRRPIGRGIEIT-GRGIKKFFSK	35	3975.87	8.1	45.71	28.57	-0.04
PD-CATH	<i>Phyllostomus discolor</i>	ILGPALRIGGRIAGRIAGKLIG-DAINRHRRERNRQR RG	37	4088.79	8.2	37.84	29.73	-0.65

<sup>a</sup> The peptide has an additional methionine at N-terminus as it was produced by a recombinant expression system [22].

a MIC of 1 µg/mL (0.2 µM). Nisin, however, was active against all Gram-positive strains in our panel with MICs of 2–16 µg/mL (0.6–3.6 µM). In contrast, interestingly, cc-CATH3, PD-CATH, and ML-CATH showed potent and broad-spectrum bactericidal activities against all bacterial species in our test panel with MICs of 2–42 µg/mL (0.5–10.6 µM).

**Potent bactericidal activities of cc-CATH3, PD-CATH, and ML-CATH against field isolates**


We also conducted an antimicrobial activity assay against field isolates from milk with high SCCs, using cc-CATH3, PD-CATH, and ML-CATH. The assay consisted of one Gram-negative (*A. hydrophila*) and 7 Gram-positive strains, including four staphylococci (*S. chromogenes*, *S. haemolyticus*, *S. xylosus*, and *S. epidermidis*), *S. uberis*, *C. simulans*, and *G. halophytocola*. As previously noted, staphylococci are a major causative bacterial genus for clinical mastitis and are commonly transmitted by contact with infected milk [3, 47]. *S. chromogenes* is also a highly prevalent species with a well-established impact on SCC in milk [48, 49]. The bactericidal potency of

cc-CATH3, PD-CATH, and ML-CATH against these field isolates was similar to those among them with MICs of 0.8–5 µg/mL (0.2–1.2 µM) except *A. hydrophila* (Table 3).

The bactericidal effect on *A. hydrophila* was observed only from PD-CATH and ML-CATH with MICs of 160 µg/mL (39.1 and 40.2 µM, respectively). This effect is much lower than the activity against other field isolates. All three AMPs demonstrated more potent antimicrobial activity against Gram-positive field isolates than the control antibiotics.

**Functional stability of cc-CATH3, PD-CATH, and ML-CATH against changes in pH and salt concentrations**

Functional stability in the physiological condition is important for clinical therapeutics. Therefore, we tested variability in the antibacterial activity of cc-CATH3, PD-CATH, and ML-CATH against *E. coli* (ATCC 25922) in response to pH and salt condition changes. Interestingly, the bactericidal activity was marginally enhanced in more acidic conditions than in neutral conditions, revealing a decrease of MICs from 3 to 2 µg/mL (0.9 to 0.6 µM) and



**Figure 1** The helical wheel modeling of 12 alpha-helical cathelicidins. **A**  $\Delta$ ModoCATH1, **B**  $\Delta$ ModoCATH5, **C**  $\Delta$ ModoCATH6, **D** PMAP-36, **E**  $\Delta$ Pb-CATH4, **F**  $\Delta$ Hg-CATH, **G** BMAP-28, **H** EA-CATH1, **I** cc-CATH3, **J** HA-CATH, **K** ML-CATH and **L** PD-CATH. Helical wheel projection diagrams were created using HeliQuest with full window size and code size proportional to amino acid volume. Nonpolar residues are shown in yellow and grey, while polar (uncharged polar, negatively, and positively charged) residues are shown in purple, red, and blue, respectively. Cysteine and proline are indicated by green color. The size of the arrow ( $\downarrow$ ) represents the level of hydrophobic moment.

from 7 to 6  $\mu\text{g}/\text{mL}$  (1.7 to 1.5  $\mu\text{M}$ ) for cc-CATH3 and PD-CATH, respectively. At the same time, ML-CATH was unaffected (2  $\mu\text{g}/\text{mL}$  or 0.5  $\mu\text{M}$ ) by pH change and a high salt concentration (150 mM sodium chloride, Table 4). The bactericidal activity of cc-CATH3 was slightly decreased, revealing an increase of MICs from 3 to 5  $\mu\text{g}/\text{mL}$  (0.9 to 1.6  $\mu\text{M}$ ) in a high salt condition. Additionally, AMPs were incubated with 50% naive FBS for 0, 60, and 120 min, respectively. The changes in antimicrobial activities against *E. coli* (ATCC 25922) were determined by measuring the bacterial cell viability over incubation time. Based on a previous study [27],  $\Delta$ Hg-CATH was used as a reference for activity loss with serum incubation. For cc-CATH3, the antimicrobial activity of the peptides was significantly affected in concentrations lower than  $3 \times \text{MIC}$  (9  $\mu\text{g}/\text{mL}$  or 2.7  $\mu\text{M}$ ) even in no prior incubation of the peptides with FBS (0 min) (Figure 2).

However, the antibacterial activities of ML-CATH and PD-CATH remained unaffected under all the tested conditions. This outcome suggests that these two bat-derived AMPs are suitable for further exploration in relation to pharmaceutical applications.

#### Low cytotoxic effects of cc-CATH3 and ML-CATH on mammalian cells

We then evaluated the viability of PK15 and HaCaT cells following incubation with 64 and 160  $\mu\text{g}/\text{mL}$  of cc-CATH3, PD-CATH, and ML-CATH each for 24 h. The results were compared with those of melittin, which is highly cytotoxic to mammalian cells (Table 5). The cytotoxicity to PK15 and HaCaT at 64  $\mu\text{g}/\text{mL}$  was minimal or unaffected, with cell viability ranging from  $91.1 \pm 1.8\%$  to  $100.6 \pm 0.4\%$  for either cc-CATH3 or ML-CATH. At the 160  $\mu\text{g}/\text{mL}$  level, HaCaT viability was

**Table 2** Bactericidal activities of cathelicidins and bacteriocins against 8 standard strains

Antimicrobials	Minimal inhibitory concentration (µg/mL, µM)							
	<i>Escherichia coli</i>	<i>Pseudomonas aeruginosa</i>	<i>Staphylococcus aureus</i>	<i>Bacillus cereus</i>	<i>Enterococcus faecalis</i>	<i>Streptococcus agalactiae</i>	<i>Streptococcus dysgalactiae</i>	<i>Streptococcus equi</i> subsp. <i>zooepidemicus</i>
ΔModoCath1	4 (1.1)	10 (2.9)	11 (3.2)	>40 (10.5)	10 (2.9)	>40 (10.5)	>40 (10.5)	40 (10.5)
ΔModoCath5	21 (5.8)	>40 (11.0)	6 (1.7)	26 (7.3)	10 (2.8)	>40 (11.0)	>40 (11.0)	>40 (11.0)
ΔModoCath6	25 (8.2)	>40 (13.2)	>40 (13.2)	>40 (13.2)	>40 (13.2)	>40 (13.2)	>40 (13.2)	>40 (13.2)
PMAP-36	3 (0.7)	8 (1.9)	9 (2.2)	28 (6.7)	>40 (9.6)	>40 (9.6)	>40 (9.6)	>40 (9.6)
PG-1	23 (10.0)	20 (8.7)	43 (18.8)	>40 (17.5)	>40 (17.5)	>40 (17.5)	32 (14.0)	>40 (17.5)
PR-35	15 (3.6)	>40 (9.5)	>40 (9.5)	>40 (9.5)	>40 (9.5)	>40 (9.5)	>40 (9.5)	>40 (9.5)
ΔPb-CATH4	5 (1.6)	11 (3.5)	4 (1.3)	>40 (13.1)	>40 (13.1)	>40 (13.1)	>40 (13.1)	20 (6.6)
ΔHg-CATH	4 (1.3)	5 (1.7)	>40 (13.2)	>40 (13.2)	>40 (13.2)	>40 (13.2)	15 (4.9)	15 (4.9)
BMAP-28	4 (1.3)	9 (2.9)	5 (1.6)	7 (2.2)	15 (4.8)	>40 (12.6)	>40 (12.6)	>40 (12.6)
EA-CATH1	9 (2.9)	19 (6.1)	41 (13.4)	>40 (13.1)	30 (9.8)	>40 (13.1)	>40 (13.1)	>40 (13.1)
cc-CATH3	3 (0.9)	4 (1.28)	2 (0.6)	4 (1.28)	5 (1.5)	4 (1.28)	7 (2.0)	5 (1.5)
HA-CATH	18 (3.9)	>40 (8.6)	26 (5.6)	25 (5.4)	>40 (8.6)	>40 (8.6)	>40 (8.6)	>40 (8.6)
ML-CATH	2 (0.5)	42 (10.6)	2 (0.5)	3 (0.8)	5 (1.3)	8 (2.0)	14 (3.5)	9 (2.3)
PD-CATH	7 (1.7)	42 (10.3)	3 (0.7)	6 (1.5)	6 (1.5)	8 (2.0)	18 (4.4)	17 (4.2)
Nisin	>64 (19.2)	>64 (19.2)	2 (0.60)	4 (1.2)	16 (3.6)	2 (0.60)	4 (1.2)	4 (1.2)
Lysostaphin	>160 (29.7)	>160 (29.7)	1 (0.2)	>160 (29.7)	>160 (29.7)	>160 (29.7)	>160 (29.7)	>160 (29.7)
Chloramphenicol <sup>a</sup>	3 (9.3)	80 (247.6)	8 (24.8)	10 (31.0)	10 (31.0)	5 (15.5)	4 (12.4)	5 (15.5)
Ampicillin <sup>a</sup>	5 (14.3)	>640 (1831.7)	2 (5.7)	80 (228.8)	10 (28.6)	4 (11.4)	2 (5.7)	2 (5.7)
Gentamicin <sup>a</sup>	1 (2.1)	1 (2.1)	1 (2.1)	1 (2.1)	90 (189.0)	75 (157.5)	15 (31.5)	45 (94.5)

<sup>a</sup> Used as controls.

*E. coli* ATCC 25922, *P. aeruginosa* ATCC 27853, *S. aureus* ATCC 6538 *B. cereus* ATCC 10876, *E. faecalis* ATCC 29212, *S. agalactiae* ATCC 27956, *S. dysgalactiae* ATCC 27957, *S. equi* subsp. *zooepidemicus* ATCC 43079.

**Table 3** Antimicrobial activity of cc-CATH3, PD-CATH, and ML-CATH against 8 field isolates from milk with high somatic cell counts

Strains	Minimal inhibitory concentration (µg/mL, µM)					
	cc-CATH3	ML-CATH	PD-CATH	Chloramphenicol <sup>a</sup>	Ampicillin <sup>a</sup>	Gentamicin <sup>a</sup>
Gram-negative bacteria <i>Aeromonas hydrophila</i>	>160 (47.4)	160 (40.2)	160 (39.1)	5 (15.5)	>240 (686.4)	4 (8.4)
Gram-positive bacteria <i>Staphylococcus chromogenes</i>	3 (0.9)	2 (0.5)	4 (1.0)	18 (55.8)	5 (14.3)	2 (4.2)
<i>Staphylococcus haemolyticus</i>	2 (0.6)	2 (0.5)	3 (0.7)	10 (31.0)	10 (28.6)	10 (20.9)
<i>Staphylococcus xylosum</i>	2 (0.6)	2 (0.5)	3 (0.7)	8 (24.8)	5 (14.3)	1 (2.1)
<i>Staphylococcus epidermidis</i>	2 (0.6)	2 (0.5)	3 (0.7)	5 (15.5)	5 (14.3)	4 (8.4)
<i>Corynebacterium simulans</i>	0.8 (0.2)	1 (0.3)	1 (0.2)	8 (24.8)	>240 (686.4)	10 (20.9)
<i>Glutamicibacter halophytocola</i>	2 (0.6)	2 (0.5)	1 (0.2)	3 (9.3)	15 (42.9)	3 (6.3)
<i>Streptococcus uberis</i>	4 (1.2)	3 (0.8)	5 (1.2)	50 (155.0)	>240 (686.4)	60 (125.6)

<sup>a</sup> Used as controls.

CLSI breakpoints of ampicillin against *Staphylococcus* spp., *Corynebacterium* spp., and *S. uberis* are ≥ 0.25, 0.125 and 0.6 µg/mL, respectively.

minimally affected with 90.1 ± 4.8% and 98.0 ± 1.5% for both cc-CATH3 and ML-CATH, respectively. However, the viability of PK15 cells was significantly reduced, with values of 32.7 ± 3.5% and 38.0 ± 2.2%, showing the dissimilarity in cytotoxic susceptibility of different cell types.

For PD-CATH, the treatment of 64 µg/mL peptides showed survivability of 43.6 ± 1.7% and 100.22 ± 0.4% for PK15 and HaCaT, respectively. The cytotoxicity at 160 µg/mL was much higher than that of the other two AMPs, with cell viability of 7.4 ± 0.2% and 11.4 ± 0.5% for the corresponding cells. When cells were treated with



**Table 4** Bactericidal activity of cc-CATH3, PD-CATH, and ML-CATH against *E. coli* under different pH and salinity

Condition	Minimal inhibitory concentration (µg/mL, µM)		
	cc-CATH3	ML-CATH	PD-CATH
pH 5	2 (0.6)	2 (0.5)	6 (1.5)
pH 6	2 (0.6)	2 (0.5)	6 (1.5)
pH 7	3 (0.9)	2 (0.5)	7 (1.7)
150 mM NaCl	5 (1.6)	2 (0.5)	7 (1.7)
Control <sup>a</sup>	3 (0.9)	2 (0.5)	7 (1.7)

<sup>a</sup> Minimum inhibitory concentration (MICs) against *E. coli* (ATCC 25922) using Mueller–Hinton Broth (MHB) at pH 7.5.

**Table 5** The influence of cc-CATH3, PD-CATH, and ML-CATH on the viability of mammalian cells under different concentrations

Peptides	Concentration (µg/mL)	Cell viability ± SD (%)	
		PK15	HaCaT
cc-CATH3	64	91.1 ± 1.8	100.6 ± 0.4
	160	32.7 ± 3.5	90.1 ± 4.8
ML-CATH	64	96.2 ± 0.4	99.7 ± 0.9
	160	38.0 ± 2.2	98.0 ± 1.5
PD-CATH	64	43.6 ± 1.7	100.2 ± 0.2
	160	7.4 ± 0.2	11.4 ± 0.5
Melittin	64	7.7 ± 0.2	7.2 ± 0.1
Triton X-100 (1%) <sup>a</sup>		13.3 ± 0.1	13.0 ± 0.4

<sup>a</sup> A control for complete cell death.


The experiment was repeated three times.

**Table 6** Haemolytic activities of cc-CATH3, PD-CATH and ML-CATH against bovine erythrocytes

Concentration (µg/mL)	cc-CATH3	ML-CATH	PD-CATH	Melittin <sup>a</sup>
10	0.0 ± 0.1	5.8 ± 0.4	0.4 ± 0.2	91.6 ± 1.0
20	0.0 ± 0.1	6.4 ± 0.8	0.7 ± 0.4	99.4 ± 0.9
40	0.4 ± 0.2	7.0 ± 0.8	2.9 ± 0.2	99.0 ± 0.3
80	0.8 ± 0.1	7.7 ± 0.2	3.5 ± 0.2	99.1 ± 0.5
160	2.3 ± 0.4	11.8 ± 4.5	4.0 ± 1.0	99.5 ± 0.3

The experiment was repeated three times.

<sup>a</sup> A control for complete cell lysis.



**Figure 2** Changes in the antibacterial activity of cc-CATH3, ML-CATH, and PD-CATH after incubation with naïve serum.

cc-CATH3, ML-CATH, and PD-CATH peptides were incubated in 50% (v/v) FBS each for 0, 60, and 120 min before applying to antimicrobial activity assay against *E. coli* (ATCC 25922). The antimicrobial activity was determined by measuring bacterial growth at OD 450 nm. The X and Y axes indicate peptide concentration and absorbance at 450 nm, respectively. Samples containing 50% FBS in the absence of the peptides indicate a control for bacterial growth without AMP treatments. The antimicrobial activity of cc-CATH3 (A), ML-CATH (B), and PD-CATH (C) after the treatment of FBS-incubated AMPs was shown.

64 µg/mL melittin as a positive control, their survivability was ~7%. Considering the MICs of cc-CATH3, PD-CATH, and ML-CATH are < 10 µg/mL across most of the tested bacterial strains, cc-CATH3 and ML-CATH cytotoxicity can be minimal to mammalian cells.

Additionally, we analysed the haemolytic effect of cc-CATH3, PD-CATH, and ML-CATH against bovine erythrocytes at different concentrations ranging from 10 to 160 µg/mL (Table 6). Melittin caused hemolysis in >90% of erythrocytes, even at the lowest level (10 µg/mL). In contrast, cc-CATH3 and PD-CATH exhibited a negligible level of haemolytic activity (2.3 ± 0.4% to 4.0 ± 1.0%) at the highest level (160 µg/mL). The haemolytic activity of ML-CATH ranged from 5.8 ± 0.4 to 11.8 ± 4.5%, which is greater than that of cc-CATH3 and PD-CATH.

**Positive correlation of cationic charges to the potency of antimicrobial peptides**

In this study, we compared the physicochemical characteristics of all evaluated AMPs to the antibacterial activity of the peptides against *E. coli* ATCC 25922 due

to their strong activity (average of MICs = 10.21 μg/mL or 3.11 μM) in opposing the strain without exception (Table 2).


Our results suggest that peptides with higher positive charges (> +6) had significantly lower MICs than those with lower charges (*p* value < 0.05, Figure 3). Further analysis on 12 helical cathelicidins in our panel also showed that cationic charge at pH 7 differs significantly between the potent and less potent peptide groups against *P. aeruginosa* (*p* value < 0.05) with the average values of 9.09 (effective group) and 4.97 (ineffective group), respectively (Figure 4 and Additional file 2). However, the other physicochemical properties, including the percentage of cationic and hydrophobic residues of the peptides, did not significantly correlate with the MICs (all  $|r| < 0.5$ ) (Additional files 3A and B). The percentage of cationic and hydrophobic residues in the peptides was predominantly distributed between the 20–50% ranges. However, most peptides were longer than 20 amino acids (Additional file 3D). This finding is consistent with previous studies [50].

**Presence of Nonpolar<sub>(n≥3)</sub>-Polar<sub>(n≥1)</sub>-Nonpolar<sub>(n≥3)</sub> motif in highly potent cathelicidins**

The predicted secondary structures of the helical cathelicidins selected in this study showed high variability in the length and average SA of the helical, strand, and coil regions (Figure 5). In more detailed analysis, we observed the presence of a unique motif “N<sub>(n≥3)</sub>-P<sub>(n≥1)</sub>-N<sub>(n≥3)</sub>” (Nonpolar<sub>(n≥3)</sub>-Polar<sub>(n≥1)</sub>-Nonpolar<sub>(n≥3)</sub>) from PMAP-36, cc-CATH3, ML-CATH, and PD-CATH, which are AMPs with potent and broad-spectrum activities. The motif was observed in the helical or strand regions of cc-CATH3, ML-CATH, and PD-CATH, whereas in PMAP-36, it was observed in the C-terminal coil region. Additionally, ML-CATH and PD-CATH feature the motif multiple times (see Figure 5).

**Discussion**


Bovine mastitis can be classified into subclinical and clinical forms according to the severity of the inflammation [51]. The degree of inflammation depends on the nature of causative pathogens, the age and breed of animals, their immunological health, and the lactation



**B**

Antibacterial activity against <i>E. coli</i>			
Average	High (charge > 6)	Low (charge < 6)	T-test ( <i>p</i> -value)
Charge at pH 7	9.07	5.18	0.0004933
MICs (μM)	1.56	6.98	0.02403

**Figure 3 Relationship between the strength of cationic charge and antibacterial activity among 14 cathelicidins. A** The minimum inhibition concentration (MIC) was differently distributed around +6 charge and indicated by red and blue circles. **B** The average of charge and MICs in each group were calculated as shown. Welch’s *t* test was used for statistical analysis.



**Figure 4** Comparison of the strength of charge and hydrophobic residue proportion among helical cathelicidins. **A** The antibacterial activity (MICs) of cathelicidins against *P. aeruginosa* (ATCC 27853) was divided into effective (< 45  $\mu$ g/mL, red circle) and ineffective (> 40  $\mu$ g/mL, blue circle) groups (Table 2 and Additional file 2). **B** The average charge and hydrophobic residue proportion for each group were calculated, as shown in the table at the bottom. Welch’s t-test was used for statistical analysis.

stage of cows [52]. Typically, antibiotic therapy is used to control infectious mastitis. However, the appearance of antimicrobial resistance in mastitis-associated pathogens such as methicillin-resistant *S. aureus* (MRSA), combined with the environment of dairy farms that act as a reservoir for antimicrobial-resistant pathogens, raises concerns about the excessive use of antibiotics [53–56]. Therefore, it is necessary to find therapeutic alternatives to antibiotic therapy for controlling the microorganisms that cause mastitis while minimising the risk of developing drug resistance.

This study underlines that AMPs could be used as possible alternatives to conventional antibiotics due to their broad-spectrum activities and, by their mechanisms, the rare probability of inducing antibiotic resistance [57]. We aimed to identify potent endogenous AMPs from animals that can fight bacterial species associated with contagious and environmental mastitis and to define their biochemical characteristics. Among the AMPs tested, ML-CATH

was the most effective in controlling the diverse mastitis-associated bacterial strains with minimal cytotoxicity to mammalian cells. During the study, we observed a unique motif “N<sub>(n≥3)</sub>-P<sub>(n≥1)</sub>-N<sub>(n≥3)</sub>” from the sequences of PMAP-36, cc-CATH3, ML-CATH, and PD-CATH with broader and stronger antimicrobial activities than the other AMPs. To our knowledge, this is the first report comparing the bactericidal activities against numerous bovine-mastitis causative bacterial species, including field isolates.

Founded on the previously established concept that cationic and hydrophobic residues of AMPs are aligned at opposite sites on their helical wheel projection, amino acid substitutions for endogenous or synthetic AMPs have inevitably been conducted accordingly. These substitutions aimed to improve the hydrophobic moment, amphipathicity, and helicity to increase antimicrobial and potentially reduce cytotoxic effects [19–21]. However, recent studies have indicated that these factors have

**The predicted secondary structure, solvent accessibility, and amino acid properties of each residue**

Cathelicidins	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40						
A M o d o C A T H 1 1	V	K	R	T	K	R	G	A	R	R	G	L	T	K	V	L	K	K	I	F	G	S	I	V	K	K	A	V	S	K	G	V														
	C	C	C	C	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	C	C	C	C											
	7	6	5	4	5	6	4	3	4	5	3	1	3	4	0	1	4	4	2	1	3	4	0	0	4	5	2	2	7	6	6	8														
	N	P	P	P	P	P	N	N	P	P	N	N	P	P	N	N	P	P	N	N	N	N	P	N	N	P	P	N	N	P	P	N	N	P	P	N	N									
A M o d o C A T H 5	W	Y	Q	L	I	R	T	F	G	N	L	I	H	Q	K	Y	R	K	L	L	E	A	Y	R	K	L	R	D																		
	C	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	C	C																	
	6	3	4	3	2	4	3	2	2	4	2	1	3	5	4	1	4	4	1	2	5	3	2	5	6	3	5	8																		
	N	P	P	N	N	P	P	N	N	P	N	N	P	P	P	P	P	N	N	N	N	P	N	P	P	P	N	P	N																	
A M o d o C A T H 1 6	V	R	R	S	K	R	G	I	K	V	P	S	F	V	K	K	V	L	K	D	V	V	S	E	S	I	S																			
	C	C	C	C	C	C	C	C	C	C	C	H	H	H	H	K	H	H	H	H	H	H	H	H	H	H	C	C																		
	8	6	5	5	5	5	4	2	5	1	2	5	2	0	4	4	1	5	4	1	2	5	6	6	3	8																				
	N	P	P	N	P	P	N	N	P	N	N	N	N	N	N	P	N	N	N	N	N	N	N	N	N	P	N	P	N																	
P M A P - 3 6	G	R	F	R	R	L	R	K	K	T	R	K	R	L	K	K	I	G	K	V	L	K	W	I	P	P	I	V	G	S	I	P	L	G	C	G										
	C	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C			
	8	5	3	5	5	2	4	6	5	3	4	6	3	1	5	5	1	3	5	2	1	5	2	2	3	4	3	3	4	4	2	4	4	4	4	3	8									
	N	P	N	P	P	N	N	P	P	N	N	N	N	N	P	N	N	N	N	N	N	N	N	N	N	N	P	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
A P b - C A T H 4	T	R	S	R	W	R	R	F	I	R	G	A	G	R	F	A	R	H	Y	G	W	R	I	A																						
	C	C	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C			
	8	6	7	4	1	3	4	1	1	4	3	1	3	4	2	1	4	4	3	4	3	4	3	8																						
	P	P	P	N	P	N	P	N	N	N	N	N	N	N	N	P	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
A H g - C A T H	S	K	F	F	R	K	A	R	K	K	L	G	K	G	L	Q	K	I	K	N	V	L	R	K	Y																					
	C	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	C																					
	8	6	3	3	5	5	1	4	6	4	2	3	5	3	1	5	4	0	4	5	2	2	6	7	6																					
	P	P	N	N	N	N	N	P	P	P	N	N	N	N	N	P	N	N	N	N	N	N	N	N	P	P	P																			
B M A P - 2 8	G	G	L	R	S	L	G	R	K	I	L	R	A	W	K	K	Y	G	P	I	V	P	I	R	I	G																				
	C	C	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	C	C	S	S	S	S	S	S	C	C																			
	8	5	4	4	5	2	4	4	4	0	1	4	3	1	5	6	3	3	3	1	1	1	3	3	2	4	4	8																		
	N	N	N	P	N	N	N	N	P	N	N	N	N	N	N	P	N	N	N	N	N	N	N	N	N	N	N	N	N																	
c c - C A T H 3	R	V	R	R	F	W	P	L	V	P	V	A	I	N	T	V	A	A	G	I	N	L	Y	K	A	I	R	R	K																	
	C	C	C	S	S	C	C	C	S	S	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	C																			
	8	4	5	4	3	2	4	2	2	3	3	3	2	4	3	2	3	3	4	1	4	1	2	5	3	2	4	7	8																	
	N	P	N	P	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N																
E A - C A T H 1	K	R	R	G	S	V	T	R	Y	Q	F	L	M	I	H	L	L	R	P	K	K	L	F	A																						
	C	C	C	C	S	S	H	H	H	H	H	H	H	H	H	H	C	C	C	C	C	C	H	H	C																					
	8	6	6	4	5	3	4	4	4	2	3	3	1	1	1	1	1	2	4	3	5	6	3	4	8																					
	P	P	P	N	N	P	N	P	P	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N																		
H A - C A T H	I	L	G	R	L	R	D	L	L	R	R	G	G	R	K	I	G	Q	G	L	E	R	I	G	Q	R	I	Q	G	F	F	S	N	R	E	P	M	E	E	S						
	C	C	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H			
	7	4	4	4	1	4	5	1	1	4	5	3	4	5	4	2	2	5	2	1	5	4	1	3	5	4	0	4	4	2	1	5	6	4	6	4	4	6	8	8						
	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N		
M L - C A T H	L	N	P	L	I	K	A	G	I	F	I	L	K	H	R	R	P	I	G	R	G	I	E	T	G	R	G	I	K	K	F	F	S	K												
	C	C	H	H	H	H	C	S	S	S	S	C	C	C	C	C	C	C	C	C	C	S	S	S	C	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H		
	8	4	3	4	2	5	2	0	1	2	1	0	4	4	4	4	4	3	4	4	1	5	2	3	3	5	2	1	4	5	3	2	7	8												
	N	P	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N		
P D - C A T H	I	L	G	P	A	L	R	I	G	G	R	I	A	G	R	I	A	G	K	L	I	G	D	A	I	N	R	H	R	E	R	N	R	Q	R	R	G									
	C	C	C	C	H	S	S	C	C	C	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H		
	7	4	3	3	3	3	4	2	3	3	4	1	2	4	4	1	2	3	4	2	1	3	4	3	1	5	4	4	4	7	5	5	4	6	6	6	8									
	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N		

**Figure 5** Comparison of amino acid sequence and structural characteristics of helical cathelicidins. Amino acid sequences are shown in the first row of each peptide. The predicted secondary structure (H: helix, S: strand, and C: coil) and solvent accessibility (values range from 0 (buried) to 8 (highly exposed residues)) for the individual residues are shown in the second and third rows of each peptide, respectively. The chemical properties corresponding to each amino acid are indicated in the fourth row of each peptide by different colors, as indicated in parentheses in the following description. "N" and "P" letters indicated nonpolar and polar, respectively. Nonpolar residues contain tryptophan (yellow), phenylalanine (yellow), and aliphatic amino acids (red), while polar residues include uncharged polar (green), positively (blue), and negatively (purple) charged residues and tyrosine (yellow). The unique motif, "N<sub>(n≥3)</sub>-P<sub>(n≥1)</sub>-N<sub>(n≥3)</sub>" was highlighted in grey.

a low correlation with antimicrobial activity and spectrum [21]. Furthermore, cc-CATH, PD-CATH, and ML-CATH, with the broadest activity spectrum and highest potency in our AMP panel, consistently presented relatively low hydrophobic moment (0.271, 0.180, and 0.372, respectively) and a less clear amphipathicity in their helical wheel projection (Table 2 and Figure 1). Conversely, the charge of AMPs appears to be a major determinant for killing Gram-negative bacteria such as *E. coli* and *P. aeruginosa*.

Previous research has also reported that the charge of AMPs acts as an important factor contributing to salt insensitivity [38]. Thus, it has been understood that highly positively charged AMPs could compete with cations and interact with the outer membrane more effectively [58]. Despite this previous reporting, the factors largely influencing antibacterial activities against Gram-positive bacteria remained unclear in our analysis, which might be attributed to the high complexity and diversity

of their cell wall composition and structure compared to those of Gram-negative bacteria [59].

In this study, the modified PMAP-36 analogs, excluding the N<sub>(n≥3)</sub>-P<sub>(n≥1)</sub>-N<sub>(n≥3)</sub> motif in the C-terminal region, showed weaker antibacterial activity and hemolysis than the parental peptide [60]. Additionally, ΔPD-CATH and ΔML-CATH, truncated forms of PD-CATH and ML-CATH, dramatically lost antimicrobial activity and cytotoxicity [32, 60]. This motif was also identified from other Aves, Reptilia, Amphibia, and Mammalia cathelicidins in public databases (Additional file 4). Therefore, further experimental validation is required to corroborate the functional importance of the N<sub>(n≥3)</sub>-P<sub>(n≥1)</sub>

and 6). It has been previously presented that the cytotoxicity of AMPs in mammalian cells varies depending on cell types, even within a species [23]. We observed similar results from PK15 and HaCaT (Table 5). Interestingly, the secondary structure of ML-CATH was symmetrical as “coil-helix-strand-coil-strand-helix-coil” (Figure 5). This structure may provide greater structural flexibility than other AMPs by offering a continuous large helix such as  $\Delta$ ModoCATH1,  $\Delta$ ModoCATH5,  $\Delta$ Pb-CATH4, and  $\Delta$ Hg-CATH to interact with bacterial membranes or cell walls.

Various AMPs are expressed in mammary epithelial cells and are upregulated in naturally occurring and experimentally induced mastitis [42, 46, 61, 62]. Among bovine cathelicidins, Bac5, indolicidin, and BMAP-28 expression was detected in somatic cells extracted from milk samples taken from cows with high SCCs. However, the expression patterns of the cathelicidin genes were significantly variable between animals [45]. For example, the expression levels of cathelicidins could depend on the duration of lactation, the presence of an infection, and the types of causative bacteria. BMAP-27 and BMAP-28 showed effective antibacterial activity against *E. coli* in standard bacterial growth media, blood serum, and whey [46]. Among the bovine cathelicidins, BMAP-28 mRNA was detected in bovine alveolar, ductal, gland cistern, and teat canal tissues from the mammary gland of healthy and experimentally infected animals with *S. aureus* [45]. It is proposed that the expression of multiple cathelicidins could, therefore, provide a synergistic effect [46].

Similar to the theory of controlling inflammatory processes using AMPs, bacteriocins can also be suggested as an approach against mastitis pathogens. Nisin, a commercially available bacteriocin produced by *Lactococcus lactis*, exhibited its inhibitory effect on several Gram-positive pathogens associated with mastitis (Table 2). This finding is consistent with previous research [40]. Another study indicated that, because of nisin's therapeutic applicability, the activity of a formulation with the peptide was comparable with chemical germicides but without skin irritation. Such an outcome can be determined by measuring the germicidal activity against mastitis pathogens on the teat skin of live cows [63].

Due to the anti-staphylococcal activity of lysostaphin, a bacteriocin produced by *Staphylococcus simulans*, we evaluated its antimicrobial effect against mastitis-associated bacteria and staphylococci in the field isolates. Based on the bacterial profiles in field isolates, staphylococci are the main causative pathogens of bovine mastitis (Table 3). Moreover, as shown in Table 2 and Additional file 6, lysostaphin showed highly specific activities at the nanomolar range against staphylococci, which could suggest its therapeutic application. As the antibacterial activity of lysostaphin has a narrow spectrum, it may be

more beneficial to utilise a combination of lysostaphin and other AMPs in treatment.

A study on the identification of mastitis pathogens in Korea classified staphylococci (52.9%) and Gram-negative bacilli (other than *Escherichia coli*, 19.5%) as major pathogens. The study also classified *Streptococcus uberis* (5.3%), *Enterococcus* spp. (4.8%), *E. coli* (4.5%), *Aerococcus* spp. (2.6%), and *Corynebacterium* spp. (1.2%) as minor pathogens [64]. The classifications of field isolates in our study were consistent with the abovementioned classifications, except for *Aeromonas hydrophila* (Additional file 1). According to CLSI breakpoints, most of the field isolates in this study displayed resistance to ampicillin based on their MICs (CLSI breakpoints  $\geq 0.25$   $\mu\text{g/mL}$ ) when compared to non-resistant strains of staphylococci (Table 3). This finding is consistent with previous studies [65]. Staphylococci, *Corynebacterium simulans*, and *A. hydrophila* were found to be susceptible to gentamicin and chloramphenicol, with MICs ranging between susceptible and intermediate levels. At the same time, *Streptococcus uberis* resisted all antibiotics (Table 3).

In contrast, cc-CATH3, ML-CATH, and PD-CATH showed highly potent bactericidal activity at a nanomolar range (MICs: 0.8–5  $\mu\text{g/mL}$  or 0.2–1.2  $\mu\text{M}$ ) against all field isolates except *A. hydrophila*. Interestingly, Bat AMPs, such as PD-CATH and ML-CATH, showed a relatively weak activity (MIC: 160  $\mu\text{g/mL}$ ) against the strain, which is a Gram-negative species found as a pathogen in reptiles, amphibians, fish, cows, and humans [66]. It has previously been reported that *A. hydrophila* showed resistance to diverse antibiotics such as erythromycin, amoxicillin, oxytetracycline, gentamicin, and kanamycin [67]. Furthermore, in a previous study analysing the biological activities of AMPs from the skin of three frog species, bactericidal activity against *A. hydrophila* was not observed [66]. These findings suggest that endogenous AMPs of animals are poorly active against *A. hydrophila*.

However, despite AMPs being a promising antimicrobial agent that can be used as an alternative to chemical antibiotics, more efforts are necessary to overcome several inherent limitations of the molecules, including high production costs, sensitivity to proteolytic degradation, and mammalian cell cytotoxicity. In this study, we successfully produced recombinant PG1 using previously reported production methods [22, 23, 68]. In doing so, we demonstrated that large-scale production of recombinant AMPs could be achieved. Moreover, few studies have investigated the in vivo efficacy of endogenous AMPs. The clinical effects of bovine lactoferrin (bLf) on staphylococcal mastitis were previously only evaluated by the intramammary infusion method, which showed that the number of staphylococci in the mammary gland was decreased in the bLf-infused group compared to that

of antibiotic therapy [69]. Therefore, historically, a gene therapy strategy to treat bovine mastitis was developed using a mammary-specific vector expressing human lysozyme (hLYZ) [70].

In this study, we presented the antibacterial activities of 16 AMPs against diverse bacterial species. Our objective was to screen promising candidates for mastitis therapeutics as an alternative to conventional antibiotics. Consequently, we demonstrated that ML-CATH could be exploited as an effective therapeutic agent in antimicrobial activity and spectrum, cytotoxicity, and physiological stability. This finding indicates that the combinatorial effects of multiple AMPs against bacterial species that show weak or no bactericidal response from treating an individual AMP may result in improved responses through synergistic effects.

Our conclusions from comparing the biochemical features of AMPs with their biological activities further illuminate relationships between their physicochemical structure and biological activity. The information on the antimicrobial properties of AMPs in this study provides a valuable contribution to developing AMP-based therapeutic agents to control various contagious bacterial diseases, including bovine mastitis.

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13567-024-01402-x>.

**Additional file 1. Identification of the field isolates from milk with high SCCs using microbiological analysis and 16S rRNA gene sequencing.** The bacterial strains were isolated from culturing milk samples of dairy cows with high SCC ( $\geq 500,000$  cells/mL) and analysed microbiological properties assessing growth, colony morphologies, and haemolytic characteristics on the blood agar plate. The isolated bacterial colonies were used to sequence the 16S rRNA gene. NCBI blast analysis against rRNA/ITS databases using the sequencing results matched to 16S rRNA sequences of known bacterial species with coverage of > 96% and identity of > 97%. The clone IDs were named "the individual number-teat position (left or right/front or rear).

**Additional file 2. Classification of analysed helical cathelicidins into two different groups according to their antimicrobial activity.** The peptides were classified into two distinct groups, "Effective" (MICs < 45  $\mu\text{g}/\text{mL}$ ) and "Ineffective" (MICs > 40  $\mu\text{g}/\text{mL}$ ) for correlation analysis. To compare the physicochemical characteristics of all helical cathelicidins evaluated in the current study to the antibacterial activity of these peptides against each bacterial strain.

**Additional file 3. Relationship between biochemical characteristics and antibacterial activity of cathelicidins.** The percentages of (A) cationic residues, (B) hydrophobic residues, and (C) the peptide length (X-axis) were compared to MIC values (Y-axis) against *E. coli* (ATCC 25922). Each peptide was presented in different colours.

**Additional file 4. Comparison of amino acid sequence and structural characteristics of 48 selected cathelicidins available in DBAASP.** (A) Amino acid sequences are shown in the first row of each peptide. The chemical properties corresponding to each amino acid are indicated in the second row of each peptide by different colours, as indicated in parentheses in the following description. "N" and "P" letters indicated non-polar and polar, respectively. Nonpolar residues contain tryptophan (yellow), phenylalanine (yellow) and aliphatic amino acids (red), while polar

residues include uncharged polar (green), positively (blue) and negatively (purple) charged residues and tyrosine (yellow). The unique motif, " $\text{N}_{(n \geq 3)}\text{-P}_{(n \geq 1)}\text{-N}_{(n \geq 3)}$ " was highlighted in grey. ID, accession ID for DBAASP. (B) Analysed cathelicidins were classified into four taxonomic groups: Aves, Reptilia, Amphibia and Mammalia. The number of the peptides containing the motif was presented in the column of " $\text{N}_{(n \geq 3)}\text{-P}_{(n \geq 1)}\text{-N}_{(n \geq 3)}$  Motif", and their ratio to the total number of peptides in each group shown the list was calculated.

**Additional file 5. Tertiary structure modelling by I-TASSER.** The tertiary structures of (A) cc-CATH3, (B) PD-CATH and (C) ML-CATH were predicted and then visualised by PyMOL as the strand structure of ML-CATH was not presented by the visualisation of PyMOL. The direction of N- to C-termini in their structures was indicated by blue to red.

**Additional file 6. Antibacterial activity of lysostaphin against staphylococci from field isolation.** The anti-staphylococcal activity of lysostaphin was evaluated against the mastitis-associated staphylococci in the field isolates, considering that staphylococci are the main causative pathogens of bovine mastitis based on the bacterial profiles in field isolates.

## Acknowledgements

We deeply thank Komipharm International Co., Ltd. (Siheung-Si, Gyeonggi-Do, Korea) for collecting the field isolates and analysing their microbiological properties.

## Authors' contributions

HC and CP designed and coordinated the study. HC, DK, HJ, and PS performed all experiments to evaluate the peptides. HC and CP analysed the data and interpreted the results. HC carried out in silico analysis. HC and CP wrote the manuscript. NS provided administrative, technical, or material support. All authors read and approved the final manuscript.

## Funding

This research was supported by grants from the National Research Foundation of Korea (NRF), which are funded by the Ministry of Science and ICT (MSIT) [2021R1A2C3010505] and the Ministry of Education [NRF-2021R1A6A3A01088087].

## Availability of data and materials

The datasets supporting the conclusions of this article are included within the article and its additional file.

## Declarations

### Competing interests

The authors declare that they have competing financial interests. The peptide sequences ML-CATH and PD-CATH were subject to domestic patent applications by Konkuk University.

Received: 28 June 2024 Accepted: 20 August 2024

Published online: 14 November 2024

## References

- Zhao X, Lacasse P (2008) Mammary tissue damage during bovine mastitis: causes and control. *J Anim Sci* 86:57–65
- Smith KL, Hogan JS (1993) Environmental mastitis. *Vet Clin North Am Food Anim Pract* 9:489–498
- Bogni C, Odierno L, Raspanti C, Giraudo J, Larriestra A, Reinoso E, Lasagno M, Ferrari M, Ducros E, Frigerio C, Bettera S, Pellegrino M, Frola I, Dieser S, Vissio C (2011) War against mastitis: Current concepts on controlling bovine mastitis pathogens. In: Méndez-Vilas A (ed) *Science against microbial pathogens: communicating current research and technological advances*, pp 483–494

4. Cvetnic L, Samardžija M, Habrun B, Kompes G, Benic M (2016) Microbiological monitoring of mastitis pathogens in the control of udder health in dairy cows. *Slov Vet Zb* 53:131–140
5. Rysanek D, Zouharova M, Babak V (2009) Monitoring major mastitis pathogens at the population level based on examination of bulk tank milk samples. *J Dairy Res* 76:117–123
6. Bramley AJ, Dodd FH (1984) Reviews of the progress of dairy science: mastitis control—progress and prospects. *J Dairy Res* 51:481–512
7. Erskine RJ, Eberhart RJ, Hutchinson LJ, Spencer SB, Campbell MA (1988) Incidence and types of clinical mastitis in dairy herds with high and low somatic cell counts. *J Am Vet Med Assoc* 192:761–765
8. Sandholm M, Kaartinen L, Pyörälä S (1990) Bovine mastitis—why does antibiotic therapy not always work? An overview. *J Vet Pharmacol Ther* 13:248–260
9. Bradley AJ, Leach KA, Breen JE, Green LE, Green MJ (2007) Survey of the incidence and aetiology of mastitis on dairy farms in England and Wales. *Vet Rec* 160:253–258
10. Vanderhaeghen W, Piepers S, Leroy F, Van Coillie E, Haesebrouck F, De Vliegher S (2015) Identification, typing, ecology and epidemiology of coagulase negative staphylococci associated with ruminants. *Vet J* 203:44–51
11. Zasloff M (2002) Antimicrobial peptides of multicellular organisms. *Nature* 415:389–395
12. Tomasinsig L, Zanetti M (2005) The cathelicidins—structure, function and evolution. *Curr Protein Pept Sci* 6:23–34
13. Crovella S, Antcheva N, Zelezetsky I, Boniotto M, Pacor S, Falzacappa MVV, Tossi A (2005) Primate  $\beta$ -defensins—structure, function and evolution. *Curr Protein Pept Sci* 6:7–21
14. Omardien S, Drijfhout JW, Zaat SA, Brul S (2018) Cationic amphipathic antimicrobial peptides perturb the inner membrane of germinated spores thus inhibiting their outgrowth. *Front Microbiol* 9:2277
15. Gogoladze G, Grigolava M, Vishnepolsky B, Chubinidze M, Duroux P, Lefranc M-P, Pirtskhalava M (2014) dbaasp: database of antimicrobial activity and structure of peptides. *FEMS Microbiol Lett* 357:63–68
16. Wang G, Li X, Wang Z (2016) APD3: the antimicrobial peptide database as a tool for research and education. *Nucl Acids Res* 44:D1087–1093
17. Laverty G, Gorman SP, Gilmore BF (2011) The potential of antimicrobial peptides as biocides. *Int J Mol Sci* 12:6566–6596
18. Peters BM, Shirliff ME, Jabra-Rizk MA (2010) Antimicrobial peptides: primeval molecules or future drugs? *PLoS Pathog* 6:e1001067
19. Sengkhui S, Klubthawee N, Aunpad R (2023) A novel designed membrane-active peptide for the control of foodborne *Salmonella enterica* Serovar Typhimurium. *Sci Rep* 13:3507
20. Klubthawee N, Adisakwattana P, Hanpithakpong W, Somsri S, Aunpad R (2020) A novel, rationally designed, hybrid antimicrobial peptide, inspired by cathelicidin and aurein, exhibits membrane-active mechanisms against *Pseudomonas aeruginosa*. *Sci Rep* 10:9117
21. Biondi B, de Pascale L, Mardirossian M, Di Stasi A, Favaro M, Scocchi M, Peggion C (2023) Structural and biological characterization of shortened derivatives of the cathelicidin PMAP-36. *Sci Rep* 13:15132
22. Soundararajan N, Cho H-s, Ahn B, Choi M, Thong LM, Choi H, Cha S-Y, Kim J-H, Park C-K, Seo K, Park C (2016) Green fluorescent protein as a scaffold for high efficiency production of functional bacteriotoxic proteins in *Escherichia coli*. *Sci Rep* 6:20661
23. Soundararajan N, Park S, Le Van CQ, Cho H-s, Raghunathan G, Ahn B, Song H, Kim J-H, Park C (2019) Protegrin-1 cytotoxicity towards mammalian cells positively correlates with the magnitude of conformational changes of the unfolded form upon cell interaction. *Sci Rep* 9:11569
24. Sebastião FA, Furlan LR, Hashimoto DT, Pilarski F (2015) Identification of bacterial fish pathogens in Brazil by direct colony PCR and 16S rRNA gene sequencing. *Adv Microbiol* 05:409
25. Galkiewicz JP, Kellogg CA (2008) Cross-kingdom amplification using bacteria-specific primers: complications for studies of coral microbial ecology. *J Appl Environ Microbiol* 74:7828–7831
26. National Center for Biotechnology Information (NCBI) rRNA/ITS databases. [https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE\\_TYPE=BlastSearch](https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch).
27. Cho H-S, Soundararajan N, Le Van CQ, Jeon H, Cha S-Y, Kang M, Ahn B, Hong K, Song H, Kim J-H, Oh K-S, Park C (2018) The novel cathelicidin of naked mole rats, Hg-CATH, showed potent antimicrobial activity and low cytotoxicity. *Gene* 676:164–170
28. Database of Antimicrobial Activity and Structure of Peptides. <https://dbaasp.org/home>.
29. ProtParam (ExpASY Proteomics Server). <http://www.expasy.org/tools/protparam.html>.
30. Protein Calculator v3.4. <http://protcalc.sourceforge.net/>.
31. Peptide 2.0 peptide hydrophobicity/hydrophilicity analysis program. [https://www.peptide2.com/N\\_peptide\\_hydrophobicity\\_hydrophilicity.php](https://www.peptide2.com/N_peptide_hydrophobicity_hydrophilicity.php).
32. HeliQuest. <http://heliquest.ipmc.cnrs.fr/>.
33. I-TASSER. <http://zhanglab.ccmb.med.umich.edu/I-TASSER/>.
34. PyMOL. <http://www.pymol.org/pymol>.
35. Taylor R (1990) Interpretation of the correlation coefficient: a basic review. *J Diagn Med Sonogr* 6:35–39
36. Kim H-Y (2019) Statistical notes for clinical researchers: the independent samples t test. *Restor Dent Endod* 44:e26
37. Steinberg DA, Hurst MA, Fujii CA, Kung AH, Ho JF, Cheng FC, Loury DJ, Fides JC (1997) Protegrin-1: a broad-spectrum, rapidly microbicidal peptide with in vivo activity. *Antimicrob Agents Chemother* 41:1738–1742
38. Cho H-s, Yum J, Larivière A, Lévêque N, Le QVC, Ahn B, Jeon H, Hong K, Soundararajan N, Kim J-H, Bodet C, Park C (2020) Opossum cathelicidins exhibit antimicrobial activity against a broad spectrum of pathogens including West Nile Virus. *Front Immunol* 11:347
39. Lu Z, Wang Y, Zhai L, Che Q, Wang H, Du S, Wang D, Feng F, Liu J, Lai R, Yu H (2010) Novel cathelicidin-derived antimicrobial peptides from *Equus asinus*. *FEBS J* 277:2329–2339
40. Broadbent JR, Chou YC, Gillies K, Kondo JK (1989) Nisin inhibits several gram-positive, mastitis-causing pathogens. *J Dairy Sci* 72:3342–3345
41. DeHart HP, Heath HE, Heath LS, LeBlanc PA, Sloan GL (1995) The lysostaphin endopeptidase resistance gene (epr) specifies modification of peptidoglycan cross bridges in *Staphylococcus simulans* and *Staphylococcus aureus*. *J Appl Environ Microbiol* 61:1475–1479
42. Strandberg Y, Gray C, Vuocolo T, Donaldson L, Broadway M, Tellam R (2005) Lipopolysaccharide and lipoteichoic acid induce different innate immune responses in bovine mammary epithelial cells. *Cytokine* 31:72–86
43. Feng F, Chen C, Zhu W, He W, Guang H, Li Z, Wang D, Liu J, Chen M, Wang Y, Yu H (2011) Gene cloning, expression and characterization of avian cathelicidin orthologs, Cc-CATHs, from *Coturnix coturnix*. *FEBS J* 278:1573–1584
44. Jeon H, Le MT, Ahn B, Cho H-s, Le VCQ, Yum J, Hong K, Kim J-H, Song H, Park C (2019) Copy number variation of PR-39 cathelicidin, and identification of PR-35, a natural variant of PR-39 with reduced mammalian cytotoxicity. *Gene* 692:88–93
45. Whelehan CJ, Barry-Reidy A, Meade KG, Eckersall PD, Chapwanya A, Narciandi F, Lloyd AT, O'Farrelly C (2014) Characterisation and expression profile of the bovine cathelicidin gene repertoire in mammary tissue. *BMC Genom* 15:128
46. Tomasinsig L, Conti GD, Skerlavaj B, Piccinini R, Mazzilli M, D'Este F, Tossi A, Zanetti M (2010) Broad-spectrum activity against bacterial mastitis pathogens and activation of mammary epithelial cells support a protective role of neutrophil cathelicidins in bovine mastitis. *Infect Immun* 78:1781–1788
47. Watts JL (1988) Etiological agents of bovine mastitis. *Vet Microbiol* 16:41–66
48. Devriese LA, Baele M, Vaneechoutte M, Martel A, Haesebrouck F (2002) Identification and antimicrobial susceptibility of *Staphylococcus chromogenes* isolates from intramammary infections of dairy cows. *Vet Microbiol* 87:175–182
49. Trinidad P, Nickerson SC, Alley TK (1990) Prevalence of intramammary infection and teat canal colonization in unbred and primigravid dairy heifers. *J Dairy Sci* 73:107–114
50. Wu M, Maier E, Benz R, Hancock REW (1999) Mechanism of interaction of different classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic membrane of *Escherichia coli*. *Biochemistry* 38:7235–7242
51. Heinze J, Donat K, Brandt HR, Wehrend A (2015) Subclinical staphylococcal intramammary infections: within-herd prevalence and effects on milk yield and somatic cell counts in Thuringian dairy herds. *Berl Munch Tierarztl Wochenschr* 128:61–69 (in German)
52. Viguier C, Arora S, Gilmartin N, Welbeck K, O'Kennedy R (2009) Mastitis detection: current trends and future perspectives. *Trends Biotechnol* 27:486–493

53. Burgos JM, Ellington BA, Varela MF (2005) Presence of multidrug-resistant enteric bacteria in dairy farm topsoil. *J Dairy Sci* 88:1391–1398
54. Cheng J, Qu W, Barkema HW, Nobrega DB, Gao J, Liu G, De Buck J, Kastelic JP, Sun H, Han B (2019) Antimicrobial resistance profiles of 5 common bovine mastitis pathogens in large Chinese dairy herds. *J Dairy Sci* 102:2416–2426
55. Nam H-M, Lee A-L, Jung S-C, Kim M-N, Jang G-C, Wee S-H, Lim S-K (2011) Antimicrobial susceptibility of *Staphylococcus aureus* and characterization of methicillin-resistant *Staphylococcus aureus* isolated from bovine mastitis in Korea. *Foodborne Pathog Dis* 8:231–238
56. Yun M-J, Yoon S, Lee YJ (2020) Monitoring and characteristics of major mastitis pathogens from bulk tank milk in Korea. *Animals* 10:1562
57. Bechinger B, Gorr SU (2017) Antimicrobial peptides: mechanisms of action and resistance. *J Dent Res* 96:254–260
58. Smart M, Rajagopal A, Liu W-K, Ha B-Y (2017) Opposing effects of cationic antimicrobial peptides and divalent cations on bacterial lipopolysaccharides. *Phys Rev E* 96:042405
59. Cummins CS, Harris H (1956) The chemical composition of the cell wall in some gram-positive bacteria and its possible value as a taxonomic character. *Microbiology* 14:583–600
60. Lyu Y, Yang Y, Lyu X, Dong N, Shan A (2016) Antimicrobial activity, improved cell selectivity and mode of action of short PMAP-36-derived peptides against bacteria and *Candida*. *Sci Rep* 6:27258
61. Günther J, Koczan D, Yang W, Nürnberg G, Reipsilber D, Schuberth H-J, Park Z, Maqbool N, Molenaar A, Seyfert H-M (2009) Assessment of the immune capacity of mammary epithelial cells: comparison with mammary tissue after challenge with *Escherichia coli*. *Vet Res* 40:31
62. Swanson KM, Stelwagen K, Dobson J, Henderson HV, Davis SR, Farr VC, Singh K (2009) Transcriptome profiling of *Streptococcus uberis*-induced mastitis reveals fundamental differences between immune gene expression in the mammary gland and in a primary cell culture model. *J Dairy Sci* 92:117–129
63. Sears PM, Smith BS, Stewart WK, Gonzalez RN, Rubino SD, Gusik SA, Kulisek ES, Projan SJ, Blackburn P (1992) Evaluation of a nisin-based germicidal formulation on teat skin of live cows. *J Dairy Sci* 75:3185–3190
64. Nam HM, Kim JM, Lim SK, Jang KC, Jung SC (2010) Infectious aetiologies of mastitis on Korean dairy farms during 2008. *Res Vet Sci* 88:372–374
65. Moon JS, Lee AR, Kang HM, Lee ES, Kim MN, Paik YH, Park YH, Joo YS, Koo HC (2007) Phenotypic and genetic antibiogram of methicillin-resistant staphylococci isolated from bovine mastitis in Korea. *J Dairy Sci* 90:1176–1185
66. Schadich E, Cole ALJ (2009) Inhibition of frog antimicrobial peptides by extracellular products of the bacterial pathogen *Aeromonas hydrophila*. *Lett Appl Microbiol* 49:384–387
67. Özavci V, Parin U, Yüksel HT, Kirkan Ş (2017) Identification of pathogen bacteria from bovine mastitis in Yozgat Province and determination of antimicrobial susceptibility. *Anim Health Prod Hyg* 6:454–458
68. Cho H-S, Choi M, Lee Y, Jeon H, Ahn B, Soundrarajan N, Hong K, Kim J-H, Park C (2021) High-quality nucleic acid isolation from hard-to-lyse bacterial strains using PMAP-36, a broad-spectrum antimicrobial peptide. *Int J Mol Sci* 22:4149
69. Kai K, Komine Y, Komine K-I, Asai K-I, Kuroishi T, Kozutsumi T, Itagaki M, Ohta M, Kumagai K (2002) Effects of bovine lactoferrin by the intramammary infusion in cows with staphylococcal mastitis during the early non-lactating period. *J Vet Med Sci* 64:873–878
70. Sun H-C, Xue F-M, Qian K, Fang H-X, Qiu H-L, Zhang X-Y, Yin Z-H (2006) Intramammary expression and therapeutic effect of a human lysozyme-expressing vector for treating bovine mastitis. *J Zhejiang Univ Sci B* 7:324–330

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.